Emergent BioSolutions Inc. EBS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Emergent BioSolutions Inc. reported revenue across 5 products and services; the largest, Product And Service, was $705M (-30.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product And Service$705Mshare n/a-30.4% yoy
- Medical Countermeasures MCM Product$457Mshare n/a-10.4% yoy
- Commercial Product$226Mshare n/a-43.3% yoy
- All Other Revenue$60.1Mshare n/a-55.4% yoy
- Contracts And Grants$37.7Mshare n/a+25.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$531M71.5%-35.4% yoy
- Other Geographical Area$137M18.4%+69.7% yoy
- Canada$75M10.1%-46.6% yoy
Members sum to the consolidated $743M for this period.
- Product And Service$150Mshare n/a-28.4% yoy
- Medical Countermeasures MCM Product$102Mshare n/a-35.0% yoy
- Commercial Product$42.9Mshare n/a-5.3% yoy
- All Other Revenue$11.4Mshare n/a-43.8% yoy
- Contracts And Grants$6.4Mshare n/a-51.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.